Clinical trials
Phase 1/2 Myelodysplastic Syndromes trials in Germany
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
17 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 1 |
| 2009 | 1 |
| 2011 | 1 |
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 2 |
| 2016 | 3 |
| 2018 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2023 | 1 |
| 2025 | 1 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 8 |
| Unknown status | 4 |
| Recruiting | 3 |
| Suspended | 1 |
| Terminated | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| AstraZeneca | 1 |
| BeOne Medicines | 1 |
| BerGenBio ASA | 1 |
| Cell Medica Ltd | 1 |
| Constellation Pharmaceuticals | 1 |
| Curis, Inc. | 1 |
| Forma Therapeutics, Inc. | 1 |
| Heinrich-Heine University, Duesseldorf | 1 |
| Johann Wolfgang Goethe University Hospital | 1 |
| Michael Luebbert | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Myelodysplastic Syndromes | 17 |
| Leukemia, Myeloid, Acute | 14 |
| Leukemia, Myelomonocytic, Chronic | 3 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 3 |
| Recurrence | 3 |
| Myelodysplastic-Myeloproliferative Diseases | 2 |
| Anemia, Aplastic | 1 |
| Bone Marrow Diseases | 1 |
| Hematologic Diseases | 1 |
| Hereditary Sensory and Autonomic Neuropathies | 1 |
Trials
Showing 1 to 17 of 17. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.